Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Yukie TsubokuraHideaki YoshimuraAtsushi SatakeYutaro NasaRyohei TsujiTomoki ItoShosaku NomuraPublished in: Immunity, inflammation and disease (2022)
LEN may be useful as a prophylactic agent for acute GVHD-induced mortality through the inhibition of lymphocyte migration to the gastrointestinal tract. Our data show the effect of LEN on immune responses early after aHSCT and suggest that cereblon, a molecular target of LEN, may be a therapeutic target for preventing acute GVHD-induced mortality.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- drug induced
- cell migration
- liver failure
- acute myeloid leukemia
- acute lymphoblastic leukemia
- immune response
- high glucose
- diabetic rats
- respiratory failure
- signaling pathway
- aortic dissection
- oxidative stress
- stem cell transplantation
- cardiovascular disease
- hepatitis b virus
- extracorporeal membrane oxygenation
- inflammatory response
- data analysis